[1]
|
C. Fiala and K. Gemzell-Danielsson, “Review of Medical Abortion Using Mifepristone in Combination with Pros-taglandin Analogue,” Contraception, Vol. 74, No. 1, 2006, pp. 66-86. doi:10.1016/j.contraception.2006.03.018
|
[2]
|
New US Food and Drug Administration Labeling on Cytotec (Misoprostol) Use and Pregnancy, “ACOG Committee Opinion 283,” American College of Obstetricians and Gynecologists, Washington DC, 2003.
|
[3]
|
M. J. Cruz, A. F. Duarte, T. Baudtier, A. P. Cunha, F. Barreto and F. Azevedo, “Lichenoid Drug Eruption Induced by Misoprostol,” Contact Dermatitis, Vol. 61, No. 4, 2009, pp. 240-242. doi:10.1111/j.1600-0536.2009.01616.x
|
[4]
|
C. Meuleman, P. Jourdain, M. Bellorini, N. Guillard, J. Loiret, B. Thebault, et al., “Anaphylactic Shock and Myocytic Necrosis after Treatment with Artotec,” Archives des Maladies du Coeur et des Vaisseaux, Vol. 95, No. 12, 2002, pp. 1230-1233.
|
[5]
|
A. A. Babakhin, H. Nolte and L. M. DuBuske, “Effect of Misoprostol on the Secretion of Histamine from Basophils of Whole Blood,” Annals of Allergy, Asthma & Immunology. Vol. 84, No. 3, 2000, pp. 361-365.
doi:10.1016/S1081-1206(10)62787-1
|
[6]
|
Y. Inoue, A. Adachi, M. Ueno, et al., “The Inhibition Effect of a Synthetic Analogue of Prostaglandin E1 to the Provocation by Aspirin in the Patients of WDEIA,” Arerugi, Vol. 58, No. 10, 2009, pp. 1418-1425.
|